Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor

Journal of International Medical Research

Volumn 27, Issue 3, 1999, Pages 107-114

  Muck W ^a   Ochmann, K ^a   Mazzu, A ^b   Lettieri, J ^b  

^a BAYER AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

Bioavailability; Biopharmaceutical profile; Cerivastatin; Pharmacokinetics

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEW DRUG;

ADULT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; FAT INTAKE; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; MALE; NIGHT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0344131935     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059902700301     Document Type: Article

References (14)

1. Angerbauer R, Bischoff H, Steinke W, et al: BAY w 6228. Drugs Future 1994; 19: 537-541.
2. Bischoff H, Angerbauer R, Bender J, et al: Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997; 135: 119-130.
3. Stein E, Sprecher D, Allenby KS, et al: Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 1997; 2: 7-16.
4. Mück W, Ritter W, Ochmann K, et al: Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol 1997; 35: 255-260.
5. Kuhlmann J, Mück W, von Keutz E, Llewelleyn M: Cerivastatin (BAY w 6228): a novel HMG-CoA reductase inhibitor. Drugs Rev 1998; 16(3): 236-263.
6. Mück W, Ochmann K, Mazzu A, et al: Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor. Atherosclerosis 1997; 134: 130.
7. Mazzu A, Lettieri J, Heller AH: Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Atherosclerosis 1997; 130 (Suppl): 29.
8. Mazzu A, Lettieri J, Kaiser L, et al: Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 1993; 53: 230.
9. Krol GJ, Beck GW, Ritter W, et al: LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993; 11: 1269-1275.
10. Azuma J: Phase I study of an antihyperlipidaemic BAY w 6228 (cerivastatin sodium) (2): results of multiple administration studies in healthy adult male volunteers. Jpn Pharmacol Ther 1996; 24 (Suppl 9): 37-53.
11. Mück W, Kawano K, Unger S, et al: Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998; 45: 583-590.
12. Azuma J: Study on bioequivalence of BAY w 6228 between 150 μg tablets, and pharmacokinetics following oral administration of BAY w 6228 in dose of 150 μg in healthy volunteers. Jpn Pharmacol Ther 1996; 24 (Suppl 9): 67-74.
13. Parker TS, McNamara DJ, Brown C, et al: Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982; 79: 3037-3041.
14. Food and Drug Administration: Guidelines for Industry. Dissolution Testing of Immediate-release Solid Oral Dosage Forms. Rockville, MD, 1997.